Esmolol

Drug Profile

Esmolol

Alternative Names: Galnobax; VLD-02

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovaLead Pharma Pvt. Ltd
  • Class Antiarrhythmics; Antihypertensives
  • Mechanism of Action Beta 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic foot ulcer

Highest Development Phases

  • Phase I/II Diabetic foot ulcer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 21 Jan 2016 Esmolol is available for licensing as of 21 Jan 2016. http://www.novaleadpharma.com/
  • 21 Jan 2016 NovaLead Pharma completes a phase I/II trial in Diabetic foot ulcer in USA, India and Malaysia prior to this date (NCT01113515)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top